HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy

HIV Medicine

Volumn 11, Issue 9, 2010, Pages 565-572

  Puthanakit, T ^a,b,c   Jourdain, G ^c   Hongsiriwon, S ^d   Suntarattiwong, P ^e   Chokephaibulkit, K ^f   Sirisanthana, V ^b,g   Kosalaraksa, P ^h   Petdachai, W ⁱ   Hansudewechakul, R ^j   Siangphoe, U ^a   Suwanlerk, T ^a   Ananworanich, J ^a,b,k  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d Regional Hospital   (Thailand)

^e QUEEN SIRIKIT NATIONAL INSTITUTE OF CHILD HEALTH   (Thailand)

^f MAHIDOL UNIVERSITY   (Thailand)

^g Faculty of Medicine Chiang Mai University   (Thailand)

^h KHON KAEN UNIVERSITY   (Thailand)

ⁱ Petchburi Hospital   (Thailand)

^j Chiang Rai Regional Hospital   (Thailand)

^k South East Asia Research Collaboration with Hawaii ^*  (Thailand)

more..

Author keywords

Children; HIV; Nonnucleoside reverse transcriptase inhibitor; Resistance mutations; Treatment failure

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE DERIVATIVE; VIRUS RNA;

ARTICLE; CHILD; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MONITORING; MUTATION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THAILAND; TREATMENT DURATION; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; PREDICTIVE VALUE OF TESTS; PREVALENCE; PYRIDAZINES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; THAILAND; TREATMENT FAILURE; VIRAL LOAD;

EID: 77955610006     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00828.x     Document Type: Article

References (26)

1. Puthanakit T, Aurpibul L, Oberdorfer P. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007, 44:599-604.
2. Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004, 39:725-731.
3. Sanchez JM, Ramos Amador JT, Fernandez de Miguel S. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J 2003, 22:863-867.
4. http://AIDSinfo.nih.gov/, Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children., Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection, February 23, 2009. US Department of Health and Human Services. Available at, (accessed 14 April 2009)
5. Chasombat S, McConnell MS, Siangphoe U. National expansion of antiretroviral treatment in Thailand, 2000-2007: program scale-up and patient outcomes. J Acquir Immune Defic Syndr 2009, 50:506-512.
6. Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L. HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24:1449-1454.
7. Kamya MR, Mayanja-Kizza H, Kambugu A. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 46:187-193.
8. Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Southeast Asian J Trop Med Public Health 2009, 40:83-88.
9. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007, 44:447-452.
10. Jayaweera DT, Espinoza L, Castro J. Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors. Expert Opin Pharmacother 2008, 9:3083-3094.
11. Johnson LB, Saravolatz LD. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin Infect Dis 2009, 48:1123-1128.
12. Madruga JV, Cahn P, Grinsztejn B. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370:29-38.
13. Johnson VA, Brun-Vezinet F, Clotet B. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008, 16:138-145.
14. Mascolini M. Monogram devises weighted genotypic score to predict etravirine response. http://www.natap.org/2008/ResisWksp/ResisWksp_31.htm, XVII International Drug Resistance Workshop, Spain. June, 2008. Available at
15. Sirivichayakul S, Ruxrungtham K, Ungsedhapand C. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS (London, England) 2003, 17:1889-1896.
16. Sohn AH, Ananworanich J. HAART for children with treatment failure. HIV Therapy 2009, 3:485-499.
17. Lapphra K, Vanprapar N, Chearskul S. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. Int J Infect Dis 2008, 12:e33-e38.
18. Jittamala P, Puthanakit T, Chaiinseeard S, Sirisanthana V. Predictors of virologic failure and genotypic resistance mutation patterns in Thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Pediatr Infect Dis J 2009, 28:826-830.
19. Prasitsuebsai W, Bowen A, Pang J, Hesp C, Kariminia A, Sohn AH. Pediatric HIV Clinical Care Resources and Management Practices in Asia: A Regional Survey of the TREAT Asia Pediatric Network. 2010 [Epub ahead of print]
20. Miller MD, Margot N, Lu B. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004, 189:837-846.
21. Hosseinipour MC, van Oosterhout JJ, Weigel R. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS (London, England) 2009, 23:1127-1134.
22. Bannister WP, Ruiz L, Cozzi-Lepri A. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS (London, England) 2008, 22:367-376.
23. Kekitinwa A, Friedman D, Coakley E, Lie Y, Graziano F. Profiling etravirine resistance in Ugandan children with extended failure of a NNRTI-inclusive regimen as first line ART. Presented at Montreal, Canada, February 8-11, 2009 [Abstract 891]
24. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. Curr HIV Res 2008, 6:474-476.
25. Gupta RK, Hill A, Sawyer AW. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:409-417.
26. Marconi A, Balestrieri M, Comastri G. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens. Clin Microbiol Infect 2009, 15:93-97.